Literature DB >> 9515132

[Proximal femoral fractures in patients over 75 years. Vital and functional prognosis of a cohort of 78 patients followed during 2.5 years].

J Tonetti1, P Couturier, A Rémy, L Nicolas, P Merloz, A Franco.   

Abstract

PURPOSE OF THE STUDY: The purpose of this study was to highlight factors influencing vital and functional prognosis at 2.5 years of elderly people being treated for a proximal femoral fracture. MATERIAL: The study was based on 78 patients more than 75 years old admitted to the orthopedic department for emergency treatment. After post-operative care, patients were transferred to a geriatric readaptation unit. The average patient age at the time of surgery was 85 years.
METHODS: This was a retrospective study. Survival graphs were established for the entire population as well as for the sub-populations characterized by a studied parameter. Mortality factors were compared via a univariable analysis. A multivariable logistical regression analysis isolated the factors explaining mortality at 12, 18, and 30 months and survival at 30 months, as well as factors explaining functional prognosis at 1 year.
RESULTS: The overall mortality rate was 41 per cent, 48.5 per cent of deaths occur within the first year. Factors which are harmful for vital prognosis are the following: high degree of dependence before the fracture, the existence of a neuropsychiatric pathology, and age factor (more than 85 years). 61.5 per cent of surviving patients were independent for daily activities. 77 per cent of surviving patients lived in their usual place of residence. Factors which were harmful for functional prognosis were the following: type of the fall, symptomatic of an underlying pathological state, and existence of a neuropsychiatric pathology. Nutrition was also a predictive factor concerning the patient's out come. DISCUSSION: The average age of the studied population was higher than in most studies in literature. The treatment is mainly based on hip arthroplasty. The group of patients of over 85 have the highest mortality rate. However, a better survival rate at 18 months has been observed for patients older than 90 years. The delay before surgical care was significantly negative if longer than 6 days. However, a delay of 3 to 6 days was not significantly harmful for survival. Within the studied population, the maximum autonomy gain was observed during the first 6 months. The type of non-accidental fall, symptomatic of an associated pathology, was a factor for functional prognosis which has not been often mentioned. So was the biological deficit of nutrition. Social status acted as an indicator of functional status evolution.
CONCLUSION: Therapeutic choices can only be guided by assessments of patients' vital and functional prognosis. A sophisticated or even expensive device should be demanded for patients with favorable prognosis. For patients with precarious functional and vital prognosis, priority should be given to less invasive techniques with immediate walking. The cost of the device should be correlated with patient's functional investment.

Entities:  

Mesh:

Year:  1997        PMID: 9515132

Source DB:  PubMed          Journal:  Rev Chir Orthop Reparatrice Appar Mot        ISSN: 0035-1040


  3 in total

1.  Economic cost of the treatment of fractures among old people: a preliminary study in dakar teaching hospital.

Authors:  Charles Bertin Diémé
Journal:  Geriatr Orthop Surg Rehabil       Date:  2014-09

2.  Prevalence of acute diseases in the elderly assisted in emergency department of orthopedics.

Authors:  Thiago de Angelis Guerra Dotta; Marcelo Batista Bonadio; Maria Elisabet Furlaneto; Jorge Dos Santos Silva; Luiz Eugênio Garcez Leme
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

3.  Incidence and risk factors of subsequent hip fractures in Korea: multicenter study.

Authors:  Kee Haeng Lee; Ju Young Kim; Soo Jae Yim; Do Hyun Moon; Geun Hong Choi; Kyoung Ho Moon
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.